File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Diabetes with poor-control HbA1c is cardiovascular disease ‘risk equivalent’ for mortality: UK Biobank and Hong Kong population-based cohort study

TitleDiabetes with poor-control HbA1c is cardiovascular disease ‘risk equivalent’ for mortality: UK Biobank and Hong Kong population-based cohort study
Authors
Issue Date1-Jan-2023
PublisherBMJ Publishing Group
Citation
BMJ Open Diabetes Research and Care, 2023, v. 11, n. 1, p. e003075 How to Cite?
Abstract

INTRODUCTION: Type 2 diabetes mellitus (T2DM) has traditionally been considered a coronary heart disease 'risk equivalent' for future mortality, but significant heterogeneity exists across people with T2DM. This study aims to determine the risk of all-cause mortality of patients with cardiovascular disease (CVD) and T2DM in UK and Hong Kong, with stratifications for hemoglobin A1 (HbA1c) concentrations, compared with those without CVD and diabetes mellitus. RESEARCH DESIGN AND METHODS: This is a retrospective cohort study of 3 839 391 adults from Hong Kong and a prospective cohort study of 497 779 adults from the UK Biobank. Individuals were divided into seven disease groups: (1) no T2DM and CVD, (2) T2DM only with HbA1c <7%, (3) T2DM only with HbA1c 7%-7.9%, (4) T2DM only with HbA1c 8%-8.9%, (5) T2DM only with HbA1c ≥9%, (6) CVD only, and (7) T2DM and CVD. Differences in all-cause mortality between groups were examined using Cox regression. RESULTS: After around 10 years of median follow-up, 423 818 and 19 844 deaths were identified in the Hong Kong cohort and UK Biobank, respectively. Compared with individuals without T2DM and CVD, the adjusted HR for all-cause mortality in the other six disease groups for the Hong Kong cohort was 1.25 (95% CI 1.23 to 1.27) for T2DM only with HbA1c [removed]


Persistent Identifierhttp://hdl.handle.net/10722/328409
ISSN
2021 Impact Factor: 4.179
2020 SCImago Journal Rankings: 1.347
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWan, EYF-
dc.contributor.authorYu, EYT-
dc.contributor.authorMak, IL-
dc.contributor.authorYoun, HM-
dc.contributor.authorChan, KS-
dc.contributor.authorChan, EWY-
dc.contributor.authorWong, ICK-
dc.contributor.authorLam, CLK-
dc.date.accessioned2023-06-28T04:44:33Z-
dc.date.available2023-06-28T04:44:33Z-
dc.date.issued2023-01-01-
dc.identifier.citationBMJ Open Diabetes Research and Care, 2023, v. 11, n. 1, p. e003075-
dc.identifier.issn2052-4897-
dc.identifier.urihttp://hdl.handle.net/10722/328409-
dc.description.abstract<p> INTRODUCTION: Type 2 diabetes mellitus (T2DM) has traditionally been considered a coronary heart disease 'risk equivalent' for future mortality, but significant heterogeneity exists across people with T2DM. This study aims to determine the risk of all-cause mortality of patients with cardiovascular disease (CVD) and T2DM in UK and Hong Kong, with stratifications for hemoglobin A1 (HbA1c) concentrations, compared with those without CVD and diabetes mellitus. RESEARCH DESIGN AND METHODS: This is a retrospective cohort study of 3 839 391 adults from Hong Kong and a prospective cohort study of 497 779 adults from the UK Biobank. Individuals were divided into seven disease groups: (1) no T2DM and CVD, (2) T2DM only with HbA1c <7%, (3) T2DM only with HbA1c 7%-7.9%, (4) T2DM only with HbA1c 8%-8.9%, (5) T2DM only with HbA1c ≥9%, (6) CVD only, and (7) T2DM and CVD. Differences in all-cause mortality between groups were examined using Cox regression. RESULTS: After around 10 years of median follow-up, 423 818 and 19 844 deaths were identified in the Hong Kong cohort and UK Biobank, respectively. Compared with individuals without T2DM and CVD, the adjusted HR for all-cause mortality in the other six disease groups for the Hong Kong cohort was 1.25 (95% CI 1.23 to 1.27) for T2DM only with HbA1c [removed] <br></p>-
dc.languageeng-
dc.publisherBMJ Publishing Group-
dc.relation.ispartofBMJ Open Diabetes Research and Care-
dc.titleDiabetes with poor-control HbA1c is cardiovascular disease ‘risk equivalent’ for mortality: UK Biobank and Hong Kong population-based cohort study-
dc.typeArticle-
dc.identifier.doi10.1136/bmjdrc-2022-003075-
dc.identifier.hkuros344607-
dc.identifier.volume11-
dc.identifier.issue1-
dc.identifier.spagee003075-
dc.identifier.eissn2052-4897-
dc.identifier.isiWOS:000914857300001-
dc.identifier.issnl2052-4897-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats